These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 1510591)

  • 1. Biologically based modeling in toxicology research.
    Andersen ME; Krishnan K; Conolly RB; McClellan RO
    Arch Toxicol Suppl; 1992; 15():217-27. PubMed ID: 1510591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologically based pharmacodynamic models: tools for toxicological research and risk assessment.
    Conolly RB; Andersen ME
    Annu Rev Pharmacol Toxicol; 1991; 31():503-23. PubMed ID: 2064384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of action and tissue dosimetry in current and future risk assessments.
    Andersen ME; Dennison JE
    Sci Total Environ; 2001 Jul; 274(1-3):3-14. PubMed ID: 11453304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a quantitative model incorporating key events in a hepatotoxic mode of action to predict tumor incidence.
    Luke NS; Sams R; DeVito MJ; Conolly RB; El-Masri HA
    Toxicol Sci; 2010 May; 115(1):253-66. PubMed ID: 20106946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue dosimetry, physiologically-based pharmacokinetic modeling, and cancer risk assessment.
    Andersen ME
    Cell Biol Toxicol; 1989 Dec; 5(4):405-15. PubMed ID: 2627676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling.
    Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF
    Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chloroform mode of action: implications for cancer risk assessment.
    Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opportunities for improving techniques for interspecies extrapolation in the risk assessment process.
    Gibson JE; Starr TB
    Environ Health Perspect; 1988 Apr; 77():99-105. PubMed ID: 3289913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of physiologically-based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures.
    Yang RS; el-Masri HA; Thomas RS; Constan AA
    Toxicol Lett; 1995 Dec; 82-83():497-504. PubMed ID: 8597101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Integrated Approach Using Publicly Available Resources for Identifying and Characterizing Chemicals of Potential Toxicity Concern: Proof-of-Concept With Chemicals That Affect Cancer Pathways.
    Iyer S; Pham N; Marty M; Sandy M; Solomon G; Zeise L
    Toxicol Sci; 2019 May; 169(1):14-24. PubMed ID: 30649495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive approach for integration of toxicity and cancer risk assessments.
    Butterworth BE; Bogdanffy MS
    Regul Toxicol Pharmacol; 1999 Feb; 29(1):23-36. PubMed ID: 10051416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk assessment of carcinogens: present status and future directions.
    Munro IC
    Biomed Environ Sci; 1988 Jun; 1(1):51-8. PubMed ID: 3077260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of the Predictive Toxicology Challenge 2000-2001.
    Helma C; Kramer S
    Bioinformatics; 2003 Jul; 19(10):1179-82. PubMed ID: 12835259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How well can in vitro data predict in vivo effects of chemicals? Rodent carcinogenicity as a case study.
    Anthony Tony Cox L; Popken DA; Kaplan AM; Plunkett LM; Becker RA
    Regul Toxicol Pharmacol; 2016 Jun; 77():54-64. PubMed ID: 26879462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment.
    el-Masri HA; Thomas RS; Benjamin SA; Yang RS
    Toxicology; 1995 Dec; 105(2-3):275-82. PubMed ID: 8571364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing computational toxicology models with phytochemicals.
    Valerio LG; Arvidson KB; Busta E; Minnier BL; Kruhlak NL; Benz RD
    Mol Nutr Food Res; 2010 Feb; 54(2):186-94. PubMed ID: 20024931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biokinetic and toxicodynamic modelling and its role in toxicological research and risk assessment.
    Blaauboer BJ
    Altern Lab Anim; 2003; 31(3):277-81. PubMed ID: 15612871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.